Boule Diagnostics AB (STU:8BD) Cyclically Adjusted FCF per Share: €0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:8BD Boule Diagnostics AB STU:8BD
47 GF Score
Price €0.48
GF Value €0.86
! 3 Warning Signs
View Full Analysis

What is Boule Diagnostics AB Cyclically Adjusted FCF per Share?

Boule Diagnostics AB STU:8BD 47 Cyclically Adjusted FCF per Share is €0.00 as of Jun. 2026. GuruFocus rates STU:8BD with a GF Score™ of 47/100 and a GF Value™ of €0.86. The stock has 3 warning signs investors should review.

Note: As Cyclically Adjusted FCF per Share is a main component used to calculate Cyclically Adjusted Price-to-FCF. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Boule Diagnostics AB's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-0.008. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.00 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -45.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Boule Diagnostics AB was -45.70% per year. The lowest was -54.20% per year. And the median was -49.95% per year.

As of today (2026-07-27), Boule Diagnostics AB's current stock price is €0.48. Boule Diagnostics AB's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €0.00. Boule Diagnostics AB's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Boule Diagnostics AB was 4907.19. The lowest was 361.53. And the median was 1106.42.


Boule Diagnostics AB  (STU:8BD) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Boule Diagnostics AB was 4907.19. The lowest was 361.53. And the median was 1106.42.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Boule Diagnostics AB Cyclically Adjusted FCF per Share Related Terms


Boule Diagnostics AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Boule Diagnostics AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boule Diagnostics AB Cyclically Adjusted FCF per Share Chart

Boule Diagnostics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 -0.01 -0.01 -0.02 -0.03

Boule Diagnostics AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.03 -0.03 0.00 0.00

STU:8BD vs ABT, SYK, MDT: Cyclically Adjusted FCF per Share Comparison

For the Medical Devices subindustry, Boule Diagnostics AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boule Diagnostics AB Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Boule Diagnostics AB's Cyclically Adjusted Price-to-FCF falls into.


STU:8BD
47GF Score
Boule Diagnostics AB STU:8BD
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Boule Diagnostics AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Boule Diagnostics AB's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.008/134.1100*134.1100
=-0.008

Current CPI (Jun. 2026) = 134.1100.

Boule Diagnostics AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 0.048 101.138 0.064
201612 0.036 102.022 0.047
201703 0.068 102.022 0.089
201706 0.008 102.752 0.010
201709 0.028 103.279 0.036
201712 0.060 103.793 0.078
201803 0.000 103.962 0.000
201806 -0.073 104.875 -0.093
201809 -0.034 105.679 -0.043
201812 -0.042 105.912 -0.053
201903 -0.062 105.886 -0.079
201906 0.009 106.742 0.011
201909 0.046 107.214 0.058
201912 0.028 107.766 0.035
202003 0.008 106.563 0.010
202006 0.019 107.498 0.024
202009 0.034 107.635 0.042
202012 0.037 108.296 0.046
202103 -0.009 108.360 -0.011
202106 -0.020 108.928 -0.025
202109 -0.005 110.338 -0.006
202112 -0.017 112.486 -0.020
202203 -0.072 114.825 -0.084
202206 -0.096 118.384 -0.109
202209 -0.112 122.296 -0.123
202212 -0.011 126.365 -0.012
202303 -0.057 127.042 -0.060
202306 -0.043 129.407 -0.045
202309 0.011 130.224 0.011
202312 0.018 131.912 0.018
202403 -0.020 132.205 -0.020
202406 -0.025 132.716 -0.025
202409 -0.026 132.304 -0.026
202412 -0.017 132.987 -0.017
202503 -0.021 132.825 -0.021
202506 -0.007 133.699 -0.007
202509 -0.001 133.480 -0.001
202512 0.019 133.390 0.019
202603 0.025 133.560 0.025
202606 -0.008 134.110 -0.008

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €0.00 mean?
Boule Diagnostics AB (STU:8BD) has a Cyclically Adjusted FCF per Share of €0.00 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Boule Diagnostics AB and its competitors.
Is Boule Diagnostics AB's Cyclically Adjusted FCF per Share too high?
Boule Diagnostics AB's current Cyclically Adjusted FCF per Share is €0.00. Overall, Boule Diagnostics AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's Cyclically Adjusted FCF per Share compare to ABT and SYK?
Boule Diagnostics AB's Cyclically Adjusted FCF per Share of €0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Boule Diagnostics AB and its competitors. Boule Diagnostics AB's current Cyclically Adjusted FCF per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (STU:8BD) has a current Cyclically Adjusted FCF per Share of €0.00. The stock's GF Value™ is €0.86, compared to a current price of €0.48 — trading 44.2% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €0.00. Boule Diagnostics AB's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Boule Diagnostics AB (STU:8BD), the current Cyclically Adjusted FCF per Share is €0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Boule Diagnostics AB (STU:8BD) Overvalued in 2026?

Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued. The current stock price of €0.48 is trading 44.2% below its estimated GF Value™ of €0.86.

Key valuation signals for STU:8BD:

  • Cyclically Adjusted FCF per Share: €0.00
  • GF Value™: €0.86 vs. price of €0.48 (44.2% below fair value)
  • GF Score™: 47/100 with 3 warning signs

No single metric tells the full story. See the STU:8BD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Boule Diagnostics AB Business Description

Other Exchanges BOUL:Sweden
Address Fagerstagatan 7, Spanga, SWE, SE-163 53
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score

Get the complete analysis for STU:8BD

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.48
Price
€0.86
GF Value